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Abstract: Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD, OMIM 609575) is associated with energy deficiency and mitochondrial dysfunction and may lead to rhabdomyolysis and
cardiomyopathy. Under physiological conditions, there is a fine balance between the utilization of
different carbon nutrients to maintain the Krebs cycle. The maintenance of steady pools of Krebs cycle
intermediates is critical formitochondrial energy homeostasis especially in high-energy demanding organs such as muscle and heart. Even-chain dicarboxylic acids are established as alternative
energy carbon sources that replenish the Krebs cycle by bypassing a defective β-oxidation pathway. Despite this, even-chain dicarboxylic acids are eliminated in the urine of VLCAD-affected
individuals. In this study, we explore dodecanedioic acid (C12; DODA) supplementation and investigate its metabolic effect on Krebs cycle intermediates, glucose uptake, and acylcarnitine profiles
in VLCAD-deficient fibroblasts. Our findings indicate that DODA supplementation replenishes the
Krebs cycle by increasing the succinate pool, attenuates glycolytic flux, and reduces levels of toxic
very long-chain acylcarnitines.
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1. Introduction
Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD, OMIM 609575) is
manifested by a wide range of clinical phenotypes including hypertrophic and dilated
cardiomyopathy, rhabdomyolysis, myopathy, and hypoglycemia [1–4]. Some of these
symptoms can be ameliorated by nutritional restrictions. Current dietary strategies are
primarily focused on eating frequent meals and avoiding consumption of very long-chain
fatty acids, instead offering carbohydrates and medium-chain triglycerides as the energy
source [5]. Despite the special diet, nutritional management has limited success to treat
some symptoms and metabolic derangements in VLCADD affected individuals.
VLCAD deficiency leads to a defect in long-chain fatty acids catabolic pathway with
subsequent disruptions in energy production [6,7] and mitochondrial function [8,9]. In high
energy demanding organs such as muscle and heart, carbon energy substrate utilization
and the maintenance of adequate pools of Krebs cycle intermediates in mitochondria
are especially critical. Disruptions in adequate energy production and mitochondrial
bioenergetic pathways are implicated in the risk of development rhabdomyolysis [10]
and cardiomyopathy [11]. To target impaired mitochondrial bioenergetics in VLCADD,
anaplerotic therapy was proposed as a new treatment strategy [12,13]. This therapeutic
approach is directed towards the restoration of energy production by replenishing pools of
Krebs cycle intermediates [14] while bypassing defective β-oxidation of long-chain fatty
acids (LCFA). Nutritional therapy with a recently FDA-approved anaplerotic triglyceride
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Figure 1. DODA oxidative metabolism in mitochondria and peroxisomes yields acetyl-CoA and succinyl-CoA that
can anaplerotically replenish the Krebs cycle (red arrows). The identity of DODA peroxisomal oxidation intermediates
transferred from peroxisome to mitochondria for further oxidation is not fully elucidated [31].
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Due to its anaplerotic effect, the pharmacokinetics of DODA were studied in humans [32–34]. Given its solubility, DODA can be introduced through peripheral veins
as an inorganic salt. Following administration, it is immediately available for the tissue
energy requirements and exhibits a very low urinary clearance [22,29]. These observations
suggest that DODA supplementation can potentially benefit some conditions associated
with energy deprivation. Limited data, however, are available on DODA metabolic effect in
comparison to the recently FDA-approved triheptanoin (DOJOVITM , Ultragenyx, Novato,
CA, USA) (Table 1).
Table 1. Biochemical and anaplerotic characteristics of triheptanoin and DODA.
Triheptanoin

DODA

•
•
•
•
•

•
•
•

•
•
•

Not water soluble
Metabolized in mitochondria
Anaplerosis: oxidized to acetyl-CoA and propionyl-CoA
Induce ketogenesis (C5 and C4 ketone bodies)
Effect on glucose metabolism: significantly decreases hypoglycemia
episodes in VLCAD affected individuals [35]
Energy characteristics: 8.3 kcal/mL (DOJOLVITM (triheptanoin) oral
liquid data from www.fda.gov (accessed on 29 June 2020))
Effect on Krebs cycle intermediates: increase plasma citrate,
aconitate, fumarate, and malate in VLCAD affected individuals [18]
Effect on lipids profile: increase in odd chain sphingomyelins,
phosphatidylcholines, and phosphatidylethanolamines in VLCAD
affected individuals [18]

•
•

•
•
•

Water-soluble
Metabolized in peroxisomes and mitochondria
Anaplerosis: oxidized to acetyl- CoA and
succinyl-CoA [22,31,36]
Does not induce ketogenesis
Effect on glucose metabolism: induces a sparing
effect on whole-body glucose uptake, in
non-insulin-dependent diabetes mellitus [23]
Energy characteristics: 7.2 kcal/g [22]
Effect on Krebs cycle intermediates: increases
succinate levels [22,31,37]
Effect on lipids profile: unknown

Here, we explore dodecanedioic acid (C12; DODA) supplementation and investigate
its metabolic effect on Krebs cycle intermediates, glucose uptake, and acylcarnitine profiles
in VLCAD-deficient fibroblasts.
2. Results
2.1. DODA Cellular Uptake
To assess DODA metabolic impact in control and VLCAD deficient cells, we first
analyzed DODA cellular uptake. Preliminary studies indicated that 1 mM DODA is the
optimum concentration that yields an increase in succinate (Figure S1). In the time period
Metabolites 2021, 11, x FOR PEER REVIEW
of sixteen hours and the presence of other competing carbon substrates such as 5 mM
glucose and 0.2 mM palmitic acid-BSA, we observed a decrease of DODA in culture media
by 22.3% and 20.0% in control and VLCAD-deficient fibroblasts, respectively (Figure 2).
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cell). 13 C6 -glucose level in cell media five hours post 1 mM DODA loading indicated
that cells consumed less glucose with fold changes of −1.50 and −4.24 for control and
VLCAD deficient cells, respectively (Figure 4A). We also monitored the incorporation
of 13 C from 13 C6 -glucose to the downstream 13 C3 -pyruvate and 13 C3 -glycolytic lactate
(Figure 4C,D). DODA has no effect on 13 C-labeled cellular pools of pyruvate and lactate
in control cells, however, there is a significant reduction of 13 C3 -pyruvate and 13 C3 lactate pools (Figure 4C,D) and their ratios (Table 2) in VLCAD-deficient fibroblasts treated
with DODA.
Table 2. Total long-chain (saturated and unsaturated C14-C18) cellular acylcarnitines.
n=5

Total Long Chain Acyl Carnitines (nmol/mg Protein)

Control
VLCAD
Control + DODA
VLCAD + DODA

91
511
103
397
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3. Discussion
Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency, a metabolic disorder
of long-chain mitochondrial fatty acids (C14-C20) oxidation, is strongly associated with
energy deficit and accumulation of toxic fatty acids oxidation intermediates. The disorder
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3. Discussion
Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency, a metabolic disorder
of long-chain mitochondrial fatty acids (C14-C20) oxidation, is strongly associated with
energy deficit and accumulation of toxic fatty acids oxidation intermediates. The disorder
is screened as a part of the newborn screening (NBS) program based on dried blood spot
acylcarnitine profiles with a follow-up second-tier testing such as urine organic acids and
molecular confirmatory tests. The defective very long-chain acyl-CoA dehydrogenase
enzyme is a key protein in mitochondrial energy metabolism, thus energy deficit and
perturbed substrate utilization play a significant role in disease pathophysiology. Disease
treatment primarily focuses on the management of clinical symptoms. Nutritional management focuses on restricting intake of dietary fat while supplementing patients with
medium-chain triglycerides (MCT oil) in an attempt to restore energy deficit and Krebs
cycle substrates balance.
A more recent therapeutic approach using anaplerotic supplements for fatty acid oxidation disorders and other inherited metabolic diseases has been proposed [38,39]. These
anaplerotic energy sources contribute to energy production by increasing the availability
of Krebs cycle intermediates or their precursors (acetyl-CoA and propionyl-CoA) required
for optimal energy production while bypassing the defective metabolic pathways [37]. For
instance, triheptanoin (DOJOLVITM ), an anaplerotic C7-triglyceride was recently approved
by FDA for LC-FOAD management. Medium even-chain dicarboxylic acids (C6-C12) also
exhibit anaplerotic characteristics and effectively replenish Krebs cycle intermediates with
efficient energetic values [21,22].
In the present study, we explored the metabolic outcomes of 1 mM DODA supplementation on Krebs cycle intermediates, acylcarnitines, and glucose uptake in fibroblasts
derived from healthy and documented VLCAD-deficient individuals.
To encourage competitive uptake of DODA, we cultured cells in a state of low glucose
(5 mM) and low palmitate-BSA (0.2 mM). Under these conditions, both control and VLCADdeficient fibroblasts consumed DODA at a similar rate, indicating that 364 A>G mutation
does not affect DODA cellular uptake (Figure 2). A number of earlier studies explored
DODA metabolism and reported that DODA catabolism yields succinate [35]. More
recently, Jin et al. perfused rat liver with 13 C-labeled DODA and detected 13 C labeling in
Krebs cycle intermediates, short-chain CoAs, and β-hydroxybutyrate. The study provides
solid evidence that DODA catabolism yields anaplerotic acetyl-CoA and succinyl-CoA in
the liver [31]. Under our experimental conditions, acyl-CoA pools were under the limit of
detection in fibroblasts however, we analyzed cellular Krebs cycle intermediates (Figure 3).
At the baseline, VLCAD deficient cells demonstrated decreased levels of succinate, α-KG,
and citrate (Figure 3). A depletion of Krebs cycle intermediates that was recently also
reported in VLCAD (−/−) mice [40] and eight VLCAD patients [18] contributes further to
energy-related impairments associated with the VLCAD phenotype.
In agreement with the anaplerotic effect of DODA reported by others, 1 mM DODA
loading resulted in an increase in succinate level in both control and VLCAD-deficient
cells by 1.17 and 1.45 fold changes, respectively. A similar fold change increase was also
observed in cellular fumarate levels. These findings support DODA anaplerotic activity. A
marked reduction in cellular citrate in both control and VLCAD-deficient fibroblasts under
DODA supplementation is consistent with the citrate synthase inhibition by the succinylCoA [41] produced from DODA. A marked reduction in cellular citrate in both control and
VLCAD-deficient fibroblasts under DODA supplementation can be possibly explained by
the succinyl-CoA inhibitory effect on citrate synthase. Tucci et al. highlight that citrate
synthase activity response is tissue-specific [42]. The study reports a decrease in wild-type
mice heart citrate synthase activity under anaplerotic triheptanoin diet with no change in
enzyme activity in VLCAD-deficient mice heart. At the same time, there is an increase in
citrate synthase activity in the liver for both wild-type and VLCAD genotypes. Although
triheptanoin is metabolized differently from DODA, it similarly results in succinyl-CoA
production. Despite the prospect that succinyl-CoA produced from DODA may lead to the
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decrease of the total cellular citrate pool, high succinyl-CoA is converted to the succinate
and may increase the respiratory activities of the electron transport chain and thus have an
overall positive impact on VLCAD deficiency-induced overall mitochondrial dysfunction.
Indeed, we found that the lactate/pyruvate ratio that represents a clinical, marker of
mitochondrial function and oxidative metabolism is normalized in VLCAD deficient cells
post DODA treatment (Table 3).
Table 3.

13 C

3

lactate/13 C3 pyruvate ratio (n = 5).
Cell Type

Control cells
VLCADD cells
Control cells/1 mM DODA
VLCADD cells/1 mM DODA

13 C

3

Lactate/13 C3 Pyruvate
2.31
3.31
2.70
2.86

Intermittent hypoglycemia is one of the clinical manifestations of fatty acid oxidation
disorders. In VLCADD, the inability to oxidize fatty acids leads to hypoketotic hypoglycemia due to a deficit in ketones as an energy source and an increase in glucose uptake
by the peripheral tissues [43]. In comparison to the control cells, VLCAD-deficient fibroblasts demonstrate a significantly higher baseline 13 C6 -glucose uptake (Figure 4), providing
evidence of metabolic adaptation to the VLCAD deficiency. At the same time, cellular
levels of 13 C3 -pyruvate in VLCAD fibroblasts were also mildly elevated suggesting that
induced glycolytic flux contributes to the excessive glucose uptake. A marked increase in
cellular 13 C3 lactate levels is a biochemical hallmark of mitochondrial dysfunction. It also
provides evidence of an increased compensatory rate of anaerobic glycolysis to meet energy
demands at the time that VLCFA utilization is restricted. An increase in lactate in our study
is in contrast to a study by Ventura et al. [44] which reported a normal lactate/pyruvate
ratio in VLCAD-deficient fibroblasts. The discrepancy in the ratios can be explained by
the heterogeneous presentation of VLCADD associated with different mutations. 1 mM
DODA loading did not significantly affect 13 C3 -lactate and 13 C3 -pyruvate levels in control
cells (Figure 4 and Table 3). The observed increase in 13 C3 -lactate/13 C3 -pyruvate in control
cells post DODA incubation from 2.31 to 2.70 is statistically insignificant as a result of a
large standard deviation in 13 C3 -lactate levels (Figure 4). In VLCAD-deficient cells, DODA
led to a decrease in lactate/pyruvate ratio that can be attributed to the attenuation of
glycolytic flux as evident by reduced glucose uptake and a decrease in the downstream
glycolytic 13 C3 -pyruvate.
Accumulation of circulating long-chain acylcarnitines is a biochemical diagnostic hallmark of VLCADD. In humans, circulating levels of acylcarnitines reflect tissue pools, and
an increase in long and long-chain acylcarnitine pools is associated with processes that are
detrimental to cardiac work [45–47]. VLCAD-deficient cells supplemented with a mixture
of fatty acids exhibit a significant accumulation of C14 and C14:2 (Figure 5) in agreement
with the VLCAD phenotype. Affected fibroblasts also demonstrated a marked decrease in
short-chain acylcarnitines C3 and C5 which is consistent with a decrease in branched-chain
amino acid utilization (BCAA). C4 acylcarnitine that derives from amino acids and lipid
metabolism was also markedly decreased. After incubation with 1mM DODA for sixteen
hours in VLCAD deficient cells, we observed a decrease in some short-chain acylcarnitines
(Figure 5) and a total concentration of long-chain acylcarnitines (C14-C18) including unsaturated species (Table 2) with the most significant changes in C14:2, C18:1 and C18:2
(Figure 5). In contrast, in control cells, DODA impact on long-chain acylcarnitines is not
significant, however, alterations in short-chain species (C3–C5) are similar to the VLCAD
deficient cells. The etiology of free carnitine decrease in control fibroblast post-DODA
addition is not clear at this moment. Intracellular C12DC carnitine was not detected, so it
is unlikely that DODA binds free carnitine and depletes carnitine pool however, we didn’t
analyze acylcarnitines that possibly eliminated to the cell media. Some anticancer drugs
(etoposide, actinomycin D, and vinblastine) and antibiotics (cephaloridine, cefepime, and
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cefluprenam, levofloxacin, and grepafloxacin) can inhibit carnitine transporter OCTN2
leading to secondary carnitine deficiency [48,49]. The clinical manifestation of the secondary carnitine deficiency was not reported in human studies with DODA. In fact, DODA
was suggested as a component of parental nutrition [22,32,50]. It is established that DODA
is first shortened in peroxisomes followed by final oxidation steps inside the mitochondria [30,31]. Once produced in peroxisomes, medium-chain acyl-CoAs are transported for
further oxidation in the mitochondria through the carnitine shuttle [31,51]. The mechanism
of the medium-chain acylcarnitines increase in cells post DODA treatment is unclear at
the moment. DODA feeding in mice induces expression of peroxisomal FAO enzymes
and MCAD/LCAD genes expression, suggesting induced production of medium-chain
acylcarnitines. More studies with stable isotope tracers are needed to clarify the increase
in medium-chain C6–C12 acylcarnitines in our cellular model. Overall, the observed acylcarnitines pattern in VLCAD deficient cells indicates that through anaplerotic acyl-CoA
production, DODA loading modifies substrate preferences, reducing utilization of BCAA
and VLCFA as carbon substrates.
While our data demonstrate DODA metabolic impact in VLCAD deficient fibroblasts
these findings however are presented in vitro cellular model. Dicarboxylic acidemia in
VLCAD deficiency is a result of compensatory and protective mechanisms where a nonmetabolized VLCFAs are channeled towards ω-oxidation. Once generated through ωoxidation mainly in the liver and kidney, DAs are activated to the corresponding CoAs and
are degraded through β-oxidation by peroxisomal and mitochondrial enzymes [30,52–54].
During fasting and metabolic instability, this protective mechanism is upregulated as
fasting induces CYP4A ω-hydroxylases and acyl CoA thioesterases (ACOTs) involved
in synthesis and degradation of DAs, respectively [55]. Indeed, when the rate of DA
production during metabolic decompensation exceeds tissue catabolic capacities, DAs
accumulate in the blood and consequently will be eliminated in urine. The metabolic effect
of DODA is also likely to be tissue-specific. Nevertheless, DODA is an alternative carbon
substrate, it is not clear to what extent the most compromised VLCAD deficient tissues
such as muscle and heart are capable to uptake it. In our study, fibroblasts consumed only
twenty-one percent of DODA (mean of control and VLCAD deficient cells) during a sixteenhour experiment, although Salinari et al. report that following DODA oral administration
in diabetes type 2 subjects the total tissue uptake is forty-seven percent [56].
The perspective and the clinical significance: The defect in VLCFA oxidation underlies
the metabolic inflexibility and aberrant energy metabolism in the heart and muscle leading
to the clinical manifestation of VLCAD deficiency. Alternative energy carbon substrates
improve cardiac symptoms and muscle energy balance during exercise performance. Dodecanedioic acid is an alternative carbon energy substrate that bypasses the defective
pathway in the course of β-oxidation and exhibits high caloric energy density. Our study
reveals that 1 mM DODA intervention leads to a decrease in glucose uptake, normalizes
lactate/pyruvate ratio, and reduces some long-chain acylcarnitines. Taken together, our
findings indicate that DODA potentially can ameliorate VLCAD symptoms, however,
additional studies are needed to elucidate DODA fate in muscle and heart as well as its
impact on metabolism during exercise.
Study limitations: VLCAD deficiency has a wide spectrum of clinical manifestation
and heterogenic phenotypic variation. Our proof-of-principle study is focused on one
single mutation. We predict that DODA metabolic response is mutation dependent whereas
further studies are needed to fully assess DODA metabolic impact with more VLCADDdeficient fibroblasts and matching control cell lines
4. Materials and Methods
4.1. Cells
Human control and VLCAD-deficient fibroblasts (364 A>G) were obtained from
Coriell Institute (control GM08680 5-month-old at sampling, disease GM17475, 10 days old
at sampling). Based on the provided characteristics, the patient has severe early onset of the
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disease, presenting with cardiomyopathy and hypoglycemia. The patient is homozygous
for an A>G transition at nucleotide 364 of the ACADVL gene resulting in an asparagine to
aspartic acid change at codon 122 in the precursor protein [Asn122Asp (N122D)]; Approval
of the Institutional Review Board was not required upon purchase. The material transfer
agreement was approved by Cleveland State University institutional board. Fibroblasts
were grown in 5 mM glucose DMEM containing 10% FBS, 100 mg/mL penicillin, 0.4 mM
L -carnitine, and 0.2 mM linoleic, oleic, and palmitic acids BSA conjugated at 37 ◦ C in
5% CO2 . For the treatment experiments, DODA was added to the cell media at a final
concentration of 1 mM. This concentration was determined empirically as the optimal
concentration for the anaplerotic effect in our system.
4.2. Dodecanedioic Acid Uptake Assay
To the 20 µL aliquot of cell media, 10 µL of undecanedioic acid (1 mM) was added
(as an internal standard) followed by the addition of 0.3 µL of 3N HCl and 300 µL of
ethyl acetate. Samples were vortexed and centrifuged at 15,000 rpm for 10 min. An
aliquot (200 µL) of the upper organic phase was transferred to a new tube and dried
at room temperature under nitrogen, followed by derivatization with 100 µL of N,OBis(trimethylsilyl)trifluoroacetamide (MilliporeSigma, Burlington, MA, USA) at 90 ◦ C for
30 min. Samples were injected onto GCMS (Agilent, Santa Clara, CA, USA) operated in electron impact (EI) mode- single ion monitoring (SIM) mode with m/z 359 and m/z 345 target
ions for dodecanedioic (Table S1) and undecanedioic acids, respectively.
4.3. Glucose Uptake Assay
Glucose uptake was assayed as described previously [57]. More details can be found
in supplemental materials.
4.4. Krebs Cycle Intermediates, Cellular Lactate, and Pyruvate
Cells were washed two times with cold Dulbecco’s phosphate-buffered saline (DPBS)
followed by one cold water wash. Metabolism quenching was achieved by the addition of
cold methanol/5% acetic acid. Cells were scraped, vortexed, then centrifuged at 5000 rpm
for 15 min. Cell lysates were separated, dried, and derivatized with methoxyamine (Millipore Sigma) in pyridine (20 mg/mL, 40 µL, 80 ◦ C for 60 min) followed by N-methyl-N-tertbutyldimethylsilyltrifluoroacetamide (MilliporeSigma 60 µL, 70 ◦ C for 45 min). Krebs cycle
intermediates were analyzed by EI-GCMS. Target ions and retention times can be found in
supplemental materials (Table S1).
4.5. Acylcarnitine Analysis
Cells were washed two times with cold Dulbecco’s phosphate-buffered saline (DPBS)
followed by one cold water wash. Metabolism quenching was achieved by the addition
of cold methanol/5% acetic acid then 100 µL of internal standard solution (Cambridge
Isotopes, Tewksbury, MA, USA, NSK B, working solution) was added. Samples were dried
under a nitrogen stream at room temperature, followed by derivatization with 60 µL of 3 N
HCl/n-butanol for 45 min at 65 ◦ C. The derivatized samples were dried and reconstituted
in mobile phase B. LC-MS/MS analysis was carried out with a SCIEX 5500 QTrap mass
spectrometer operated in +ESI/multiple reaction monitoring scans (MRM). Chromatography and mass spectrometry method details can be found in supplemental materials
(Tables S2–S4).
4.6. Statistical Analysis
Relative metabolites levels or percent fraction of 13 C labeled metabolite are given
as mean ± SD. There were five biological replicates for each condition. Significance was
tested with Student’s t-test. A difference of p ≤ 0.05 was considered significant.
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Supplementary Materials: Supplementary materials can be found at https://www.mdpi.com/
article/10.3390/metabo11080538/s1. Figure S1: Optimization of DODA concentration. Change
in succinate level in normal fibroblasts in different DODA concentrations (6 h), Figure S2: DODA
EI-GCMS spectrum as trimethylsilyl derivative, Figure S3: Total ion chromatogram. EI-GCMS,
Table S1: Target ions as tert-Butyltrimethylsilyl derivatives, Table S2: LC gradient program for acyl
carnitines analysis, Table S3: Acylcarnitines mass spectrometry parameters, Table S4: Acylcarnitines
retention times.
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